Select Publications
Journal articles
2017, 'Action plan for optimizing the design of clinical trials in chronic kidney disease', Kidney International Supplements, 7, pp. 138 - 144, http://dx.doi.org/10.1016/j.kisu.2017.07.009
,2017, 'Closing the gap between evidence and practice in chronic kidney disease', Kidney International Supplements, 7, pp. 114 - 121, http://dx.doi.org/10.1016/j.kisu.2017.07.006
,2017, 'Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis', PLoS ONE, 12, pp. e0184398, http://dx.doi.org/10.1371/journal.pone.0184398
,2017, 'Composite primary end points in cardiovascular outcomes trials involving type 2 diabetes patients: Should unstable angina be included in the primary end point?', Diabetes Care, 40, pp. 1144 - 1151, http://dx.doi.org/10.2337/dc17-0068
,2017, 'Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial', Drugs in R and D, 17, pp. 441 - 448, http://dx.doi.org/10.1007/s40268-017-0201-0
,2017, 'Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data', The Lancet Diabetes and Endocrinology, 5, pp. 718 - 728, http://dx.doi.org/10.1016/S2213-8587(17)30183-3
,2017, 'Canagliflozin and cardiovascular and renal events in type 2 diabetes', New England Journal of Medicine, 377, pp. 644 - 657, http://dx.doi.org/10.1056/NEJMoa1611925
,2017, 'Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial', JAMA - Journal of the American Medical Association, 318, pp. 432 - 442, http://dx.doi.org/10.1001/jama.2017.9362
,2017, 'Reanalysis of the crystalloid versus hydroxyethyl starch trial (CHEST)', New England Journal of Medicine, 377, pp. 298 - 300, http://dx.doi.org/10.1056/NEJMc1703337
,2017, 'Association of positive airway pressure with cardiovascular events and death in adults with sleep apnea: A systematic review and meta-analysis', JAMA - Journal of the American Medical Association, 318, pp. 156 - 166, http://dx.doi.org/10.1001/jama.2017.7967
,2017, 'Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial', Nephrology, 22, pp. 548 - 554, http://dx.doi.org/10.1111/nep.12815
,2017, 'Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials', Diabetes, Obesity and Metabolism, 19, pp. 926 - 935, http://dx.doi.org/10.1111/dom.12924
,2017, 'A trial of extending hemodialysis hours and quality of life', Journal of the American Society of Nephrology, 28, pp. 1898 - 1911, http://dx.doi.org/10.1681/ASN.2015111225
,2017, 'Chronic kidney disease in Asia: Protocol for a collaborative overview', Nephrology, 22, pp. 456 - 462, http://dx.doi.org/10.1111/nep.12821
,2017, 'Warfarin Initiation, Atrial Fibrillation, and Kidney Function: Comparative Effectiveness and Safety of Warfarin in Older Adults With Newly Diagnosed Atrial Fibrillation', American Journal of Kidney Diseases, 69, pp. 734 - 743, http://dx.doi.org/10.1053/j.ajkd.2016.10.018
,2017, 'SO019EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL', Nephrology Dialysis Transplantation, 32, pp. iii12 - iii12, http://dx.doi.org/10.1093/ndt/gfx103
,2017, 'SP259EFFECTS OF EMPAGLIFLOZIN ON RENAL OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL', Nephrology Dialysis Transplantation, 32, pp. iii193 - iii194, http://dx.doi.org/10.1093/ndt/gfx145.sp259
,2017, 'The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy', Diabetes, Obesity and Metabolism, 19, pp. 749 - 753, http://dx.doi.org/10.1111/dom.12864
,2017, 'Comparison of exposure response relationship of atrasentan between North American and Asian populations', Diabetes, Obesity and Metabolism, 19, pp. 545 - 552, http://dx.doi.org/10.1111/dom.12851
,2017, 'Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS-R): A randomized, placebo-controlled trial', Diabetes, Obesity and Metabolism, 19, pp. 387 - 393, http://dx.doi.org/10.1111/dom.12829
,2017, 'Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients', Cochrane Database of Systematic Reviews, 2017, http://dx.doi.org/10.1002/14651858.CD009966.pub2
,2017, 'Canagliflozin slows progression of renal function decline independently of glycemic effects', Journal of the American Society of Nephrology, 28, pp. 368 - 375, http://dx.doi.org/10.1681/ASN.2016030278
,2017, 'Chronic kidney disease and the global NCDs agenda', BMJ Global Health, 2, http://dx.doi.org/10.1136/bmjgh-2017-000380
,2017, 'Comparative Effectiveness of 12 Treatment Strategies for Preventing Contrast-Induced Acute Kidney Injury: A Systematic Review and Bayesian Network Meta-analysis', American Journal of Kidney Diseases, 69, pp. 69 - 77, http://dx.doi.org/10.1053/j.ajkd.2016.07.033
,2017, 'Side effects and tolerability of combination blood pressure lowering according to blood pressure levels: An analysis of the PROGRESS and ADVANCEtrials', Journal of Hypertension, 35, pp. 1318 - 1325, http://dx.doi.org/10.1097/HJH.0000000000001287
,2016, 'Commentary', Annals of Internal Medicine, 165, pp. JC71, http://dx.doi.org/10.7326/ACPJC-2016-165-12-071
,2016, 'Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference', Kidney International, 90, pp. 1175 - 1183, http://dx.doi.org/10.1016/j.kint.2016.09.010
,2016, 'A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension', The Lancet, 388, pp. 2665 - 2712, http://dx.doi.org/10.1016/S0140-6736(16)31134-5
,2016, 'Knowing what we do not know: statin therapy in advanced chronic kidney disease', The Lancet Diabetes and Endocrinology, 4, pp. 801 - 803, http://dx.doi.org/10.1016/S2213-8587(16)30192-9
,2016, 'The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis', American Journal of Kidney Diseases, 68, pp. 591 - 598, http://dx.doi.org/10.1053/j.ajkd.2016.04.011
,2016, 'The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis', American Journal of Kidney Diseases, 68, pp. 554 - 563, http://dx.doi.org/10.1053/j.ajkd.2016.03.418
,2016, 'Sharing data from cardiovascular clinical trials \- a proposal', New England Journal of Medicine, 375, pp. 407 - 409, http://dx.doi.org/10.1056/NEJMp1605260
,2016, 'Effects of the mediterranean diet on cardiovascular outcomes-a systematic review and meta-analysis', PLoS ONE, 11, pp. e0159252, http://dx.doi.org/10.1371/journal.pone.0159252
,2016, 'Guideline for the diagnosis and management of hypertension in adults — 2016', Medical Journal of Australia, 205, pp. 85 - 89, http://dx.doi.org/10.5694/mja16.00526
,2016, 'Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF', Journal of the American College of Cardiology, 67, pp. 2888 - 2899, http://dx.doi.org/10.1016/j.jacc.2016.02.082
,2016, 'A randomized trial of intensive versus standard blood-pressure control [10]', New England Journal of Medicine, 374, pp. 2295, http://dx.doi.org/10.1056/NEJMc1602668
,2016, 'The β-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) feasibility study: A randomized controlled trial', American Journal of Kidney Diseases, 67, pp. 902 - 911, http://dx.doi.org/10.1053/j.ajkd.2015.10.029
,2016, 'Interventions for lowering plasma homocysteine levels in dialysis patients', Cochrane Database of Systematic Reviews, 2016, http://dx.doi.org/10.1002/14651858.CD004683.pub4
,2016, 'Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: A systematic review and meta-analysis', The Lancet Diabetes and Endocrinology, 4, pp. 411 - 419, http://dx.doi.org/10.1016/S2213-8587(16)00052-8
,2016, 'Long-term benefits of intensive glucose Control for preventing end-stage kidney disease: ADVANCE-ON', Diabetes Care, 39, pp. 694 - 700, http://dx.doi.org/10.2337/dc15-2322
,2016, 'Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers', European Journal of Preventive Cardiology, 23, pp. 758 - 768, http://dx.doi.org/10.1177/2047487315598709
,2016, 'Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients with CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials', American Journal of Kidney Diseases, 67, pp. 728 - 741, http://dx.doi.org/10.1053/j.ajkd.2015.10.011
,2016, 'Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease', Cochrane Database of Systematic Reviews, 2016, http://dx.doi.org/10.1002/14651858.CD009631.pub2
,2016, 'ALTITUDE: Defining a ceiling for blockade of the renin-angiotensin system?', The Lancet Diabetes and Endocrinology, 4, pp. 289 - 290, http://dx.doi.org/10.1016/S2213-8587(15)00518-5
,2016, 'The Affordable Dialysis Prize steams ahead', The Lancet, 387, pp. 1040, http://dx.doi.org/10.1016/S0140-6736(16)00657-7
,2016, 'International trials in middle-income countries: different local scenarios require different ethical approaches', Journal of the Royal Society of Medicine, 109, pp. 47 - 51, http://dx.doi.org/10.1177/0141076815608854
,2016, 'Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: Updated systematic review and meta-analysis', The Lancet, 387, pp. 435 - 443, http://dx.doi.org/10.1016/S0140-6736(15)00805-3
,2016, 'The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial', Redox Report, 21, pp. 14 - 23, http://dx.doi.org/10.1179/1351000215Y.0000000022
,2016, 'Effects of ischaemic conditioning on major clinical outcomes in people undergoing invasive procedures: Systematic review and meta-analysis', BMJ (Online), 355, http://dx.doi.org/10.1136/bmj.i5599
,2016, 'Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes', Diabetes, Obesity and Metabolism, 18, pp. 82 - 91, http://dx.doi.org/10.1111/dom.12589
,